1. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis 
Edwin Bronsky, MDa, Peter Boggs, MDb, Steven Findlay, MDc, Sandra Gawchik, DOd, John Georgitis, MDe, Herbert Mansmann, MDf, Lawrence Sholler, MDg, James Wolfe, MDh, Eli Meltzer, MDi, Richard Morris, MDj, Zev Munk, MDk, Barry Paull, MDl, Warren Pleskow, MDm, Paul Ratner, MDn, Melvyn Danzig, PhDo, Judy Harrison, MDo, Richard Lorber, MDo 
Journal of Allergy and Clinical Immunology 
Volume 96, Issue 2, Pages (August 1995)
DOI: /S (95)
Copyright © 1995 Mosby, Inc. Terms and Conditions

2. FIG. 1
Mean reduction from baseline in mean total symptoms. Sum of rhinorrhea, stuffiness, itching, sneezing, itching or burning eyes, tearing, redness, itching of ears or palate. On day 4: SCH 434 QD and loratadine versus pseudoephedrine and placebo, p ≤ At end point: SCH 434 QD versus loratadine, pseudoephedrine, and placebo, p ≤ Overall: SCH 434 QD and loratadine versus placebo, p ≤ 0.01; SCH 434 QD versus pseudoephedrine, p < 0.01.
Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) )
Copyright © 1995 Mosby, Inc. Terms and Conditions

3. FIG. 2
Mean reduction from baseline in mean total nasal symptoms. Sum of rhinorrhea, stuffiness, itching, and sneezing. On day 4: all active treatments versus placebo, p < 0.01; SCH 434 QD versus pseudoephedrine, p = At end point: SCH 434 QD versus placebo, p < 0.01; SCH 434 QD versus loratadine, p < 0.01; pseudoephedrine versus placebo, p < Overall: all active treatments versus placebo, p < 0.01.
Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) )
Copyright © 1995 Mosby, Inc. Terms and Conditions

4. FIG. 3
Mean reduction from baseline in mean total nonnasal symptoms. Sum of burning or itching eyes, tearing eyes, red eyes, and itching of ears or palate. On day 4: SCH 434 QD versus placebo and pseudoephedrine, p < 0.01; loratadine versus pseudoephedrine and placebo, p < At end point: SCH 434 QD versus placebo and pseudoephedrine, p < 0.01; loratadine versus pseudoephedrine and placebo, p ≤ Overall: SCH 434 QD and loratadine versus pseudoephedrine and placebo, p < 0.01.
Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) )
Copyright © 1995 Mosby, Inc. Terms and Conditions

5. FIG. 4
Mean reduction from baseline in mean nasal stuffiness. On day 4 and at end point: SCH 434 QD versus placebo, p ≤ 0.03; pseudoephedrine versus placebo, p ≤ At end point: SCH 434 QD and pseudoephedrine versus loratadine, p < Overall: SCH 434 QD versus loratadine and placebo, p ≤ 0.02; pseudoephedrine versus placebo, p = 0.04.
Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) )
Copyright © 1995 Mosby, Inc. Terms and Conditions